Takeda Oncology
Abner Lobao, MD, is a seasoned medical affairs leader with extensive experience in oncology and Latin America. Currently serving as Vice President of US Medical Affairs Oncology at Takeda Oncology, Abner previously held key positions at Takeda, including Executive Director of Medical Affairs in Brazil and Head of Medical & Scientific Affairs for Latin America. Prior roles at Johnson & Johnson encompassed Regional Senior Director of Medical Affairs & Education and Regional Medical & Regulatory Affairs Director for Latin America, as well as Group Medical Manager at The Janssen Pharmaceutical Companies of Johnson & Johnson. Abner obtained a Doctor of Medicine (MD) degree from Faculdade de Ciências Médicas da Santa Casa de São Paulo and completed a General Surgery Residency Program in Ob/Gyn at Unifesp - Universidade Federal de São Paulo.
Takeda Oncology
20 followers
In 2008, Takeda Pharmaceutical Company Limited acquired Millennium Pharmaceuticals and the resulting company became exclusively focused on oncology. In 2014, Takeda Oncology was created to become the global headquarters for Takeda’s oncology specialty business unit, in Cambridge, Massachusetts, on the former Millennium Pharmaceuticals site. AtTakeda Oncology they endeavor to deliver novel medicines to patients with cancer worldwide through our commitment to science, breakthrough innovation and passion for improving the lives of patients. This singular focus drives our aspirations to discover, develop and deliver breakthrough oncology therapies. By concentrating the power of leading scientific minds and the vast resources of a global pharmaceutical company, they are finding innovative ways to improve the treatment of cancer.They've built a portfolio of paradigm-changing therapies and a leading oncology pipeline. Though They've made great strides in our fight against cancer, they are determined to do more — to work harder and to reach higher. They continue to seek our aspirations with the same passion, agility and entrepreneurial spirit that has sustained our patient-centric culture and has made us the leaders in oncology that they are today.